Compare · APT vs EW
APT vs EW
Side-by-side comparison of Alpha Pro Tech Ltd. (APT) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APT and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $47.58B, about 944.6x APT ($50.4M).
- Over the past year, APT is up 4.2% and EW is up 5.3% - EW leads by 1.2 points.
- EW has hit the wire 8 times in the past 4 weeks while APT has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for APT).
- Company
- Alpha Pro Tech Ltd.
- Edwards Lifesciences Corporation
- Price
- $5.01+1.83%
- $82.65-1.31%
- Market cap
- $50.4M
- $47.58B
- 1M return
- -3.65%
- -7.80%
- 1Y return
- +4.16%
- +5.33%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2000
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Alpha Pro Tech Ltd.
Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through two segments, Disposable Protective Apparel and Building Supply. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap, synthetic roof underlayment, and other woven materials. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites; and pharmaceutical markets. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest APT
- Alpha Pro Tech Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Garcia David R exercised 4,900 units of options at a strike of $4.23 and sold $34,421 worth of shares (6,186 units at $5.56), decreasing direct ownership by 6% to 19,768 units (SEC Form 4)
- Director Garcia David R sold $28,788 worth of shares (4,900 units at $5.88) and exercised 4,900 units of options at a strike of $3.99 (SEC Form 4)
- SEC Form 144 filed by Alpha Pro Tech Ltd.
- Director Montgomery Charles D sold $152,319 worth of shares (23,886 units at $6.38), decreasing direct ownership by 49% to 25,281 units (SEC Form 4)
- SEC Form 10-Q filed by Alpha Pro Tech Ltd.
- Alpha Pro Tech Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alpha Pro Tech, Ltd. Announces First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by Alpha Pro Tech Ltd.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Pro Tech Ltd.
Latest EW
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves